The Latest Breaking News from Ulcerative Colitis

European Commission (EC) has approved AbbVie’s (NYSE:ABBV) lead asset RINVOQ (upadacitinib 45 mg [induction dose] and 15 mg and 30 mg [maintenance doses]) for the treatment of adult patients with moderately to severely active ulcerative colitis. AbbVie shares traded in a range of $150.33 to $153.56 on a day volume…

Here's a roundup of top developments in the biotech space over the last 24 hours:

DEAR MAYO CLINIC: My husband is 45 and has lived with irritable bowel syndrome for many years. He was recently diagnosed with primary sclerosing cholangitis. Are these two conditions related? We were told a liver transplant was likely in the future. Do all people require a transplant? Are other treatments…

Applied Molecular Transport Inc (NASDAQ: AMTI) has 

Catherine Hopkins started suffering swollen joints, belly pain and chronic fatigue at the age of 27 and was diagnosed with ulcerative colitis which has had a major impact on her quality of life

Seres Therapeutics Inc (NASDAQ:MCRB) announced confirmatory results from ECOSPOR IV, an open-label study for SER-109 to prevent recurrent C. difficile infection (rCDI).  The overall safety profile observed in ECOSPOR IV through 24 weeks indicated that SER-109 was well tolerated. The ECOSPOR III and ECOSPOR IV studies conclude the SER-109 Phase 3 development program. In ECOSPOR…

Ryan Brown's family are planning to submit a formal complaint to NHS Lanarkshire as they believe he received "a neglectful lack of care".

Ryan Brown's sister Hope believes there were multiple missed opportunities to diagnosis her sibling and is calling for more frequent testing for patients with ulcerative colitis.

Eli Lilly And Co (NYSE:LLY) announced a data readout for the Lucent-2 Phase 3 study of mirikizumab after 52 weeks. The trial enrolled patients with ulcerative colitis who had initially responded to mirikizumab in a 12-week Lucent-1 study. The primary endpoint was clinical remission, with 49.9% of participants in the mirikizumab arm reaching…

Pfizer Inc (NYSE:PFE) has announced detailed results from two pivotal studies from ELEVATE UC Phase 3 program evaluating etrasimod for active ulcerative colitis (UC).  The drug, etrasimod, was Pfizer's key asset in its $6.7 billion deal for Arena Pharmaceuticals last year.  UC is an inflammatory bowel disease that affects around 3.8 million people in North…

Surrozen, Inc. (NASDAQ: SRZN) announced that the first patient has been dosed in the Phase 1 clinical trial to evaluate its drug candidate SZN-1326 for the potential treatment of moderate to severe ulcerative colitis.